Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People pass by the sign for the annual general meeting of Novo Nordisk at the entrance of the meeting hall on March 26, 2026 in Copenhagen, Denmark.
Tom Small | Reuters
Novo Nordisk The Danish drugmaker said Tuesday it is partnering with OpenAI to “bring new and better treatment options to patients faster.”
The partnership will enable Novo to better use artificial intelligence to analyze complex data sets, identify promising new drugs and reduce the time it takes for a drug to move from research to patient use, the company said in a statement.
“There are millions of people living with obesity and diabetes who need treatment options, and we know there are treatments still waiting to be discovered that could change their lives,” said Novo CEO Mike Doustdar. “Integrating AI into our daily work gives us the ability to analyze data sets at a previously impossible scale, identify patterns we cannot see, and test hypotheses faster than ever before.”
“Artificial intelligence is reshaping industries and in the life sciences can help people live better and longer lives,” said OpenAI CEO Sam Altman.
This is breaking news. Please refresh for updates.
